Dr. Markman on Immune Targeting in Ovarian Cancer

Maurie Markman, MD
Published: Friday, Jan 13, 2017



Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the development of immune targeting in ovarian cancer.

There is sound scientific reasoning to believe that immune targeting of ovarian cancer makes sense, says Markman. Although current trials have been disappointing, interest in checkpoint inhibitors has come to the forefront.

According to Markman, the most important aspect of developing immune targeting in ovarian cancer is coming up with clinically reasonable biomarkers.

Next steps in development would be obtaining these biomarkers. Randomized phase III trials are being initiated, but Markman says that it would be more beneficial to focus on finding powerful biomarkers first rather than waiting for these trials to run their course.
 


Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the development of immune targeting in ovarian cancer.

There is sound scientific reasoning to believe that immune targeting of ovarian cancer makes sense, says Markman. Although current trials have been disappointing, interest in checkpoint inhibitors has come to the forefront.

According to Markman, the most important aspect of developing immune targeting in ovarian cancer is coming up with clinically reasonable biomarkers.

Next steps in development would be obtaining these biomarkers. Randomized phase III trials are being initiated, but Markman says that it would be more beneficial to focus on finding powerful biomarkers first rather than waiting for these trials to run their course.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x